Zurcher Kantonalbank Zurich Cantonalbank Grows Position in TESARO Inc (TSRO)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of TESARO Inc (NASDAQ:TSRO) by 18.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,497 shares of the biopharmaceutical company’s stock after acquiring an additional 539 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in TESARO were worth $260,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Gateway Investment Advisers LLC increased its stake in TESARO by 0.9% during the 4th quarter. Gateway Investment Advisers LLC now owns 26,133 shares of the biopharmaceutical company’s stock worth $1,940,000 after acquiring an additional 223 shares during the period. Kistler Tiffany Companies LLC increased its stake in TESARO by 166.7% during the 4th quarter. Kistler Tiffany Companies LLC now owns 400 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 250 shares during the period. Miracle Mile Advisors LLC increased its stake in TESARO by 4.0% during the 4th quarter. Miracle Mile Advisors LLC now owns 7,850 shares of the biopharmaceutical company’s stock worth $583,000 after acquiring an additional 300 shares during the period. Commonwealth Equity Services LLC increased its stake in TESARO by 13.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,822 shares of the biopharmaceutical company’s stock worth $734,000 after acquiring an additional 2,218 shares during the period. Finally, US Bancorp DE increased its stake in TESARO by 163.5% during the 3rd quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 2,445 shares during the period.

A number of research firms have commented on TSRO. BidaskClub lowered TESARO from a “buy” rating to a “hold” rating in a research note on Thursday, January 17th. HC Wainwright lowered TESARO from a “buy” rating to a “neutral” rating in a research note on Friday, December 7th. Leerink Swann lifted their price target on TESARO from $48.00 to $75.00 and gave the company a “market perform” rating in a research note on Sunday, December 9th. Barclays lowered TESARO from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $48.00 to $75.00 in a research note on Sunday, December 9th. Finally, Cantor Fitzgerald lowered TESARO from an “overweight” rating to a “neutral” rating in a research note on Wednesday, December 5th. Eighteen investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $79.05.



TSRO stock traded up $0.02 during midday trading on Monday, reaching $74.96. 1,191,003 shares of the stock were exchanged, compared to its average volume of 1,970,604. The firm has a market capitalization of $4.13 billion, a P/E ratio of -8.17 and a beta of 0.38. TESARO Inc has a 52 week low of $23.41 and a 52 week high of $75.16.

TRADEMARK VIOLATION WARNING: “Zurcher Kantonalbank Zurich Cantonalbank Grows Position in TESARO Inc (TSRO)” was first posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://dakotafinancialnews.com/2019/02/11/zurcher-kantonalbank-zurich-cantonalbank-grows-position-in-tesaro-inc-tsro.html.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Recommended Story: QQQ ETF

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply